Cyclosporine and Graft-versus-Host Disease after Bone Marrow Transplantation

H. Schmidt, H. Einsele, K. Jaschonek, R. Dopfer, G. Ehninger, Arnold Glazier, Gary C Yee, H. Joachim Deeg

Research output: Contribution to journalLetter

2 Citations (Scopus)

Abstract

To the Editor: The findings of Yee et al. (July 14 issue)1 accord with our recent data, which also suggest a correlation between trough concentrations of cyclosporine in plasma and the manifestations of graft-versus-host disease (GVHD) after bone marrow transplantation. During the past five years, 65 patients (17 with acute lymphoblastic leukemia, 15 with acute nonlymphoblastic leukemia, 18 with chronic myelogenous leukemia, 12 with severe aplastic anemia, and 3 with neuroblastoma, stage IV; median age, 23 — range, 2 to 48) received cyclosporine to prevent GVHD. Bone marrow was obtained from HLA-identical, mixed leukocyte culture–negative siblings. All patients received cyclosporine.

Original languageEnglish (US)
Pages (from-to)1607-1608
Number of pages2
JournalNew England Journal of Medicine
Volume319
Issue number24
DOIs
StatePublished - Dec 15 1988

Fingerprint

Graft vs Host Disease
Bone Marrow Transplantation
Cyclosporine
Aplastic Anemia
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Neuroblastoma
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Acute Myeloid Leukemia
Siblings
Leukocytes
Bone Marrow

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Schmidt, H., Einsele, H., Jaschonek, K., Dopfer, R., Ehninger, G., Glazier, A., ... Deeg, H. J. (1988). Cyclosporine and Graft-versus-Host Disease after Bone Marrow Transplantation. New England Journal of Medicine, 319(24), 1607-1608. https://doi.org/10.1056/NEJM198812153192414

Cyclosporine and Graft-versus-Host Disease after Bone Marrow Transplantation. / Schmidt, H.; Einsele, H.; Jaschonek, K.; Dopfer, R.; Ehninger, G.; Glazier, Arnold; Yee, Gary C; Deeg, H. Joachim.

In: New England Journal of Medicine, Vol. 319, No. 24, 15.12.1988, p. 1607-1608.

Research output: Contribution to journalLetter

Schmidt, H, Einsele, H, Jaschonek, K, Dopfer, R, Ehninger, G, Glazier, A, Yee, GC & Deeg, HJ 1988, 'Cyclosporine and Graft-versus-Host Disease after Bone Marrow Transplantation', New England Journal of Medicine, vol. 319, no. 24, pp. 1607-1608. https://doi.org/10.1056/NEJM198812153192414
Schmidt H, Einsele H, Jaschonek K, Dopfer R, Ehninger G, Glazier A et al. Cyclosporine and Graft-versus-Host Disease after Bone Marrow Transplantation. New England Journal of Medicine. 1988 Dec 15;319(24):1607-1608. https://doi.org/10.1056/NEJM198812153192414
Schmidt, H. ; Einsele, H. ; Jaschonek, K. ; Dopfer, R. ; Ehninger, G. ; Glazier, Arnold ; Yee, Gary C ; Deeg, H. Joachim. / Cyclosporine and Graft-versus-Host Disease after Bone Marrow Transplantation. In: New England Journal of Medicine. 1988 ; Vol. 319, No. 24. pp. 1607-1608.
@article{f34211e25a024a2ea4ae597cbbd6a473,
title = "Cyclosporine and Graft-versus-Host Disease after Bone Marrow Transplantation",
abstract = "To the Editor: The findings of Yee et al. (July 14 issue)1 accord with our recent data, which also suggest a correlation between trough concentrations of cyclosporine in plasma and the manifestations of graft-versus-host disease (GVHD) after bone marrow transplantation. During the past five years, 65 patients (17 with acute lymphoblastic leukemia, 15 with acute nonlymphoblastic leukemia, 18 with chronic myelogenous leukemia, 12 with severe aplastic anemia, and 3 with neuroblastoma, stage IV; median age, 23 — range, 2 to 48) received cyclosporine to prevent GVHD. Bone marrow was obtained from HLA-identical, mixed leukocyte culture–negative siblings. All patients received cyclosporine.",
author = "H. Schmidt and H. Einsele and K. Jaschonek and R. Dopfer and G. Ehninger and Arnold Glazier and Yee, {Gary C} and Deeg, {H. Joachim}",
year = "1988",
month = "12",
day = "15",
doi = "10.1056/NEJM198812153192414",
language = "English (US)",
volume = "319",
pages = "1607--1608",
journal = "New England Journal of Medicine",
issn = "0028-4793",
publisher = "Massachussetts Medical Society",
number = "24",

}

TY - JOUR

T1 - Cyclosporine and Graft-versus-Host Disease after Bone Marrow Transplantation

AU - Schmidt, H.

AU - Einsele, H.

AU - Jaschonek, K.

AU - Dopfer, R.

AU - Ehninger, G.

AU - Glazier, Arnold

AU - Yee, Gary C

AU - Deeg, H. Joachim

PY - 1988/12/15

Y1 - 1988/12/15

N2 - To the Editor: The findings of Yee et al. (July 14 issue)1 accord with our recent data, which also suggest a correlation between trough concentrations of cyclosporine in plasma and the manifestations of graft-versus-host disease (GVHD) after bone marrow transplantation. During the past five years, 65 patients (17 with acute lymphoblastic leukemia, 15 with acute nonlymphoblastic leukemia, 18 with chronic myelogenous leukemia, 12 with severe aplastic anemia, and 3 with neuroblastoma, stage IV; median age, 23 — range, 2 to 48) received cyclosporine to prevent GVHD. Bone marrow was obtained from HLA-identical, mixed leukocyte culture–negative siblings. All patients received cyclosporine.

AB - To the Editor: The findings of Yee et al. (July 14 issue)1 accord with our recent data, which also suggest a correlation between trough concentrations of cyclosporine in plasma and the manifestations of graft-versus-host disease (GVHD) after bone marrow transplantation. During the past five years, 65 patients (17 with acute lymphoblastic leukemia, 15 with acute nonlymphoblastic leukemia, 18 with chronic myelogenous leukemia, 12 with severe aplastic anemia, and 3 with neuroblastoma, stage IV; median age, 23 — range, 2 to 48) received cyclosporine to prevent GVHD. Bone marrow was obtained from HLA-identical, mixed leukocyte culture–negative siblings. All patients received cyclosporine.

UR - http://www.scopus.com/inward/record.url?scp=0024202566&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0024202566&partnerID=8YFLogxK

U2 - 10.1056/NEJM198812153192414

DO - 10.1056/NEJM198812153192414

M3 - Letter

VL - 319

SP - 1607

EP - 1608

JO - New England Journal of Medicine

JF - New England Journal of Medicine

SN - 0028-4793

IS - 24

ER -